Romiplostim (Nplate®)

Assessment Status Rapid Review Complete
Drug Romiplostim
Brand Nplate®
Indication Is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.
Assessment Process
Rapid review commissioned 02/04/2015
Rapid review completed 27/05/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.